TSN222 in Subjects With Advanced Solid Tumors or Lymphomas

This is a Phase 1/2 study testing TSN222, a new investigational drug, in people with advanced solid tumors (cancers in organs) or lymphomas that have not responded to standard treatments. The study first determines the safest and most effective dose, then assesses how well it works. **You may be eligible if...** - You are 18 or older - You have an advanced solid tumor or lymphoma with no good remaining standard treatment options - Your cancer has at least one measurable tumor visible on scans - You are in relatively good health (able to carry out normal daily activity with at most mild limitations) - Your life expectancy is at least 3 months and you are willing to provide tumor tissue samples **You may NOT be eligible if...** - You have active, untreated, or unstable brain metastases (cancer spread to the brain) - You have serious autoimmune disease, uncontrolled infection, or significant organ dysfunction - You are pregnant or breastfeeding - You have been treated with other investigational drugs very recently Talk to your doctor to see if this trial is right for you.